Effect of Intravitreal Bevacizumab on Non -Age-Related Macular Degeneration (AMD) Related Choroidal Neovascularization (CNV)

Phase 3

Completed

• Conditions: Choroidal Neovascularization
• Interventions: Drug: bevacizumab

• Registration Number: NCT00370786
• Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary

To evaluate the effect of bevacizumab for treatment of non-AMD choroidal neovascularization (CNV); eg:angioid streaks, ocular histoplasmosis, high myopia, idiopathic,etc

Detailed Description

Not available

Study Timeline

• Study Start: 2005-11
• Study First Submitted: 2006-08-30
• Study First Submitted QC: 2006-08-30
• Study First Posted: 2006-09-01
• Primary Completion: 2007-11
• Study Completion: 2008-02
• Status Verified: 2008-07
• Last Update Submitted: 2008-07-09
• Last Update Posted: 2008-07-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 31

Inclusion Criteria

• Cases with subfoveal or juxtafoveal CNV due to a non-AMD related cause.

Exclusion Criteria

• Evidence of AMD

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
1	bevacizumab	-

Primary Outcome Measures

Name	Time	Method
Visual acuity	6 months

Secondary Outcome Measures

Name	Time	Method
central macular thickness	6 months
leakage in fluorescein angiography	6 months

Trial Locations

Locations (1)

Hamid Ahmadieh, MD; 🇮🇷 Tehran, Iran, Islamic Republic of